US 12,485,207 B2
Implant with antiproliferative active substance limited to abluminal side and method of production
André Goepfert, Alt Sammit (DE)
Assigned to BIOTRONIK AG, Buelach (CH)
Appl. No. 17/260,893
Filed by BIOTRONIK AG, Buelach (CH)
PCT Filed Aug. 14, 2019, PCT No. PCT/EP2019/071832
§ 371(c)(1), (2) Date Jan. 15, 2021,
PCT Pub. No. WO2020/038800, PCT Pub. Date Feb. 27, 2020.
Claims priority of application No. 18190387 (EP), filed on Aug. 23, 2018.
Prior Publication US 2021/0252198 A1, Aug. 19, 2021
Int. Cl. A61L 31/16 (2006.01); A61K 31/337 (2006.01); A61L 31/02 (2006.01); A61L 31/10 (2006.01); C08L 67/04 (2006.01)
CPC A61L 31/16 (2013.01) [A61K 31/337 (2013.01); A61L 31/022 (2013.01); A61L 31/10 (2013.01); C08L 67/04 (2013.01); A61L 2300/416 (2013.01); A61L 2300/608 (2013.01); A61L 2420/02 (2013.01); A61L 2420/08 (2013.01)] 17 Claims
 
1. An implant, consisting of:
a degradable main body defining a lumen, wherein the main body consists of a magnesium degradable alloy;
a degradable coating comprising at least one degradable polymer, the degradable coating substantially completely enclosing the main body on its luminal and abluminal sides; and
an antiproliferative active substance consisting only of the antiproliferative active substance itself applied upon the degradable coating only on the abluminal side of the main body, wherein the degradable coating contains no active substance and the antiproliferative active substance is not in mixture with the degradable coating, wherein the antiproliferative active substance is paclitaxel or an mTOR inhibitor, wherein the mTOR inhibitor is selected from one of the following
sirolimus;
everolimus;
zotarolimus
temsirolimus;
biolimus A9
ridaforolimus; or
a compound according to formula I, wherein formula I is

OG Complex Work Unit Chemistry
in which R is C(O)—(CH2)n-X, n is 0, 1 or 2, and X is a cyclic hydrocarbon having 3-9 carbon atoms, which optionally contains one or more unsaturated bonds.